Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorICIs Appear Safer Than TKIs for Advanced Hepatocellular Carcinoma

The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form